Literature DB >> 26997087

Evolving Indications for Tips.

Mitchell Smith1, Janette Durham2.   

Abstract

Transjugular intrahepatic portosystemic shunt creation is a well-established therapy for refractory variceal bleeding and refractory ascites in patients who do not tolerate repeated large volume paracentesis. Experience and technical improvements including covered stents have led to improved TIPS outcomes that have encouraged an expanded application. Evidence for other less frequent indications continues to accumulate, including the indications of primary prophylaxis in patients with high-risk acute variceal bleeding, gastric and ectopic variceal bleeding, primary treatment of medically refractory ascites, recurrent refractory ascites following liver transplantation, hepatic hydrothorax, hepatorenal syndrome, Budd-Chiari syndrome, and portal vein thrombosis. Treatment of patients with high-risk acute variceal bleeding with early TIPS and using transjugular intrahepatic portosystemic shunts as a primary therapy rather than large volume paracentesis for refractory ascites would likely be the 2 circumstances that permit expansion in the frequency of TIPS procedures. The remaining populations discussed above are relatively rare.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  TIPS indications; cirrhotic ascites; high-risk variceal bleeding; portal hypertension complications

Mesh:

Year:  2016        PMID: 26997087     DOI: 10.1053/j.tvir.2016.01.004

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  6 in total

1.  Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study.

Authors:  Maria Stepanova; Fatema Nader; Christophe Bureau; Danielle Adebayo; Laure Elkrief; Dominique Valla; Markus Peck-Radosavljevic; Anne McCune; Victor Vargas; Macarena Simon-Talero; Juan Cordoba; Paolo Angeli; Silvia Rossi; Stewart MacDonald; Jeroen Capel; Rajiv Jalan; Zobair M Younossi
Journal:  Qual Life Res       Date:  2018-02-19       Impact factor: 4.147

2.  Chinese guidelines on the management of ascites and its related complications in cirrhosis.

Authors:  Xiaoyuan Xu; Zhongping Duan; Huiguo Ding; Wengang Li; Jidong Jia; Lai Wei; Enqiang Linghu; Hui Zhuang
Journal:  Hepatol Int       Date:  2019-01-18       Impact factor: 6.047

3.  A Case of Budd-Chiari Syndrome Associated With Antiphospholipid Syndrome Treated Successfully by Transjugular Intrahepatic Portosystemic Shunt.

Authors:  Ege Sinan Torun; Mert Erciyestepe; Yasemin Yalçınkaya; Ahmet Gül; Murat İnanç; Lale Öcal; Sabahattin Kaymakoğlu; Bora Peynircioğlu; Bahar Artım-Esen
Journal:  Clin Med Insights Case Rep       Date:  2022-05-18

4.  Transjugular Intrahepatic Portosystemic Shunt as the Treatment for Refractory Hepatic Hydrothorax with Portal Vein Thrombosis.

Authors:  Lin-Hao Zhang; Huan Tong; Bo Wei; Hao Wu; Cheng-Wei Tang
Journal:  Chin Med J (Engl)       Date:  2017-08-20       Impact factor: 2.628

5.  Covered versus bare stents for transjugular intrahepatic portosystemic shunt: an updated meta-analysis of randomized controlled trials.

Authors:  Xingshun Qi; Yulong Tian; Wei Zhang; Zhiping Yang; Xiaozhong Guo
Journal:  Therap Adv Gastroenterol       Date:  2016-10-20       Impact factor: 4.409

6.  Hepatorenal syndrome: role of the transjugular intrahepatic stent shunt in real life practice.

Authors:  Gianni Testino
Journal:  Clujul Med       Date:  2017-10-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.